## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.3% below STRENGTH zone (4.0-10.0%); PEG 3.69 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (45% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. Medtronic (MDT) Stock: Dividend Timing, MiniMed IPO Watch, and What to Know Before the Next NYSE Session**
- Source: ts2.tech | 20251227T213541 | Somewhat-Bullish | Relevance: 100%
- Medtronic (NYSE: MDT) is heading into the weekend with investors considering its recently passed dividend record date, the planned MiniMed IPO to separate its diabetes business, and strong cardiovascular momentum. The stock closed Friday at $96.52, with thin trading volumes typical for the year-end "Santa rally" period. Over the weekend and leading into next week's trading, investors will be focused on MiniMed IPO developments, upcoming macro catalysts like Federal Reserve minutes, and Medtronic's Q3 FY26 earnings report expected around February 17, 2026.

**2. Medtronic (MDT) Stock After Hours on Dec. 24, 2025: FDA Class I Recall Headline, Options Surge, Dividend Timing, and What to Watch Before Markets Reopen**
- Source: ts2.tech | 20251225T040833 | Neutral | Relevance: 100%
- Medtronic (MDT) faced a Class I FDA recall for its DLP Left Heart Vent Catheters on December 24, 2025, a serious issue that could impact market sentiment. Despite this, the stock saw unusually heavy options activity, especially in call options, and investors are also closely watching the ex-dividend date on December 26, 2025, which could mechanically influence the stock price. The upcoming MiniMed IPO and general market conditions will also be key factors for MDT as markets reopen after the holiday.

**3. FDA Flags Medtronic Heart Catheter Recall As Most Serious Safety Risk**
- Source: Benzinga | 20251224T140848 | Bearish | Relevance: 100%
- The U.S. Food and Drug Administration has issued a Class I recall, its most serious category, for certain Medtronic Left Heart Vent Catheters due to safety concerns. These catheters, used during cardiopulmonary bypass, may fail to maintain their shape, potentially causing tissue abrasion, perforation, or even death. Medtronic has reported three serious injuries related to this issue and no deaths as of July 28.

**4. Medtronic (MDT) Stock Update: Dividend Timing, MiniMed IPO Catalyst, and What Investors Should Watch Before Mondayâ€™s Open**
- Source: ts2.tech | 20251228T213828 | Somewhat-Bullish | Relevance: 100%
- This article provides investors with key updates on Medtronic (MDT) ahead of Monday's market open, focusing on its recent stock performance, upcoming dividend schedule, and significant catalysts like the MiniMed IPO and Hugo robotic surgery FDA clearance. It also touches on analyst forecasts and regulatory news impacting the medical technology giant. The overall sentiment suggests a constructive market backdrop for Medtronic, driven by strategic portfolio moves and growth drivers in cardiovascular and robotics.

**5. Medtronic PLC $MDT Shares Purchased by Columbus Macro LLC**
- Source: MarketBeat | 20251228T093634 | Bullish | Relevance: 100%
- Columbus Macro LLC increased its stake in Medtronic PLC (NYSE:MDT) by 19.2% in the third quarter, bringing their total holdings to 85,748 shares valued at $8.17 million. Medtronic recently surpassed earnings expectations with $1.36 EPS and $8.96B revenue, announced a quarterly dividend of $0.71, and boasts a consensus "Moderate Buy" rating from analysts. The medical technology company's stock currently trades at $96.52 with a market capitalization of $123.7 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.7x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.69 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $123.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.69 |
| Forward P/E | 15.8 |
| Current P/E | 17.1 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.9% to -4.3% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.3pp (needs >4.0% for momentum thesis). AM_20 at -3.4% indicates price below own 20MA trend. Underperforming sector by 4.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-0.59), momentum weakening. Volume at 45% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.26% (CS: 12) | Weak |
| RSI_14 | 38.7 | Neutral |
| MACD Histogram | -0.59 | Bearish |
| vs SMA20 | 0.966x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.058x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.54
- **Stop Loss:** $93.56 (3.1% risk)
- **Target:** $99.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 442
- **Position Value:** $42,670.68
- **Portfolio %:** 42.67%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*